Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.
An NIH-sponsored study assessed boosters for adults fully vaccinated with any authorized or approved COVID-19 vaccine.
New vaccine approach triggers neutralizing antibody production and T-cell responses and lowers risk of infection.
Older and immunocompromised people and those with underlying health conditions could benefit most from additional shots.
People with blood cancers and those on chemotherapy may not respond adequately to their first two vaccine doses.
None of the available coronavirus vaccines have been linked to increased risk of HIV acquisition or disease progression.
Many people who received any of the authorized COVID-19 vaccines are now eligible for an additional dose of their choice.
People who received the Moderna COVID-19 vaccine had strong immune memory of SARS-CoV-2 six months after vaccination.
Third booster dose may improve immune response in cancer patients without sufficient protection after second dose.
A growing number of Americans are contending with the disturbing experience of getting COVID despite having had one shot, or even two.
Natural immunity and vaccine responses may be weaker in people with immune suppression, so they should get their second dose promptly.
Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.
A slow vaccine rollout and the emergence of new coronavirus mutations threaten progress in reducing new cases and death.
The technology used in COVID-19 vaccines may also be used to prevent other viral infections and to treat cancer and multiple sclerosis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.